Now showing items 1-18 of 18

    • Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors 

      Akbay, E; Koyama, S.; Carretero, J.; Altabef, A.; Tchaicha, J. H.; Christensen, Camilla Laulund; Mikse, O. R.; Cherniack, Andrew David; Beauchamp, Ellen Monica; Pugh, T; Wilkerson, M. D.; Fecci, P; Butaney, M.; Reibel, J. B.; Soucheray, M.; Cohoon, T. J.; Janne, Pasi Antero; Meyerson, Matthew Langer; Hayes, D. N.; Shapiro, Geoffrey Ira; Shimamura, T; Sholl, Lynette Marie; Rodig, Scott J.; Freeman, Gordon James; Hammerman, Peter Seth; Dranoff, G; Wong, Kwok-Kin (American Association for Cancer Research (AACR), 2013)
      The success in lung cancer therapy with Programmed Death (PD)-1 blockade suggests that immune escape mechanisms contribute to lung tumor pathogenesis. We identified a correlation between Epidermal Growth Factor Receptor ...
    • Antileukemic Activity of Nuclear Export Inhibitors that Spare Normal Hematopoietic Cells 

      Etchin, Julia; Sun, Q; Kentsis, Alex; Farmer, A; Zhang, Z C; Sanda, Takaomi; Mansour, M R; Barcelo, C; McCauley, D; Kauffman, M; Shacham, S; Christie, A L; Kung, A L; Rodig, Scott J.; Chook, Y M; Look, A. Thomas (Nature Publishing Group, 2013)
      Drugs that target the chief mediator of nuclear export, chromosome region maintenance 1 protein (CRM1) have potential as therapeutics for leukemia, but existing CRM1 inhibitors show variable potencies and a broad range of ...
    • Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer 

      Strickland, Kyle C.; Howitt, Brooke E.; Shukla, Sachet A.; Rodig, Scott; Ritterhouse, Lauren L.; Liu, Joyce F.; Garber, Judy E.; Chowdhury, Dipanjan; Wu, Catherine J.; D'Andrea, Alan D.; Matulonis, Ursula A.; Konstantinopoulos, Panagiotis A. (Impact Journals LLC, 2016)
      Immune checkpoint inhibitors (e.g., anti-PD-1 and anti-PD-L1 antibodies) have demonstrated remarkable efficacy against hypermutated cancers such as melanomas and lung carcinomas. One explanation for this effect is that ...
    • Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1 

      Howitt, Brooke Elizabeth; Shukla, Sachet; Sholl, Lynette Marie; Ritterhouse, Lauren Lee; Watkins, Jaclyn Christine; Rodig, Scott J.; Stover, Elizabeth Harmon; Strickland, Kyle Craig; D'Andrea, Alan David; Wu, Catherine Ju-Ying; Matulonis, Ursula Anne; Konstantinopoulos, Panagiotis (American Medical Association (AMA), 2015)
      Importance Immune checkpoint inhibitor therapy has shown benefit in various cancers, but their potential in endometrial cancer (EC) is unknown. Observations Prediction of neoantigen load was performed using sequencing ...
    • Autocrine Activation of the MET Receptor Tyrosine Kinase in Acute Myeloid Leukemia 

      Kentsis, Alex; Reed, Casie; Rice, Kim L.; Sanda, Takaomi; Rodig, Scott J.; Tholouli, Eleni; Christie, Amanda; Valk, Peter J.M.; Delwel, Ruud; Ngo, Vu; Kutok, Jeffery Lorne; Dahlberg, Suzanne E.; Moreau, Lisa A.; Byers, Richard J.; Christensen, James G.; Woude, George Vande; Licht, Jonathan D.; Kung, Andrew L.; Staudt, Louis M.; Look, A. Thomas (Nature Publishing Group, 2012)
      Although the treatment of acute myeloid leukemia (AML) has improved significantly, more than half of all patients develop disease that is refractory to intensive chemotherapy. Functional genomics approaches offer a means ...
    • Comprehensive analyses of tumor immunity: implications for cancer immunotherapy 

      Li, Bo; Severson, Eric; Pignon, Jean-Christophe; Zhao, Haoquan; Li, Taiwen; Novak, Jesse; Jiang, Peng; Shen, Hui; Aster, Jon C.; Rodig, Scott; Signoretti, Sabina; Liu, Jun S.; Liu, X. Shirley (BioMed Central, 2016)
      Background: Understanding the interactions between tumor and the host immune system is critical to finding prognostic biomarkers, reducing drug resistance, and developing new therapies. Novel computational methods are ...
    • Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry 

      Kluk, Michael J.; Ashworth, Todd; Wang, Hongfang; Knoechel, Birgit; Mason, Emily F.; Morgan, Elizabeth A.; Dorfman, David; Pinkus, Geraldine; Weigert, Oliver; Hornick, Jason L.; Chirieac, Lucian R.; Hirsch, Michelle; Oh, David J.; South, Andrew P.; Leigh, Irene M.; Pourreyron, Celine; Cassidy, Andrew J.; DeAngelo, Daniel J.; Weinstock, David M.; Krop, Ian E.; Dillon, Deborah; Brock, Jane E.; Lazar, Alexander J. F.; Peto, Myron; Cho, Raymond J.; Stoeck, Alexander; Haines, Brian B.; Sathayanrayanan, Sriram; Rodig, Scott; Aster, Jon C. (Public Library of Science, 2013)
      Fixed, paraffin-embedded (FPE) tissues are a potentially rich resource for studying the role of NOTCH1 in cancer and other pathologies, but tests that reliably detect activated NOTCH1 (NICD1) in FPE samples have been ...
    • Identification of ALK Gene Alterations in Urothelial Carcinoma 

      Bellmunt, Joaquim; Selvarajah, Shamini; Rodig, Scott; Salido, Marta; de Muga, Silvia; Costa, Irmgard; Bellosillo, Beatriz; Werner, Lillian; Mullane, Stephanie; Fay, André P.; O'Brien, Robert; Barretina, Jordi; Minoche, André E.; Signoretti, Sabina; Montagut, Clara; Himmelbauer, Heinz; Berman, David M.; Kantoff, Philip; Choueiri, Toni K.; Rosenberg, Jonathan E. (Public Library of Science, 2014)
      Background: Anaplastic lymphoma kinase (ALK) genomic alterations have emerged as a potent predictor of benefit from treatment with ALK inhibitors in several cancers. Currently, there is no information about ALK gene ...
    • Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma 

      Du, Ziming; Abedalthagafi, Malak; Aizer, Ayal A.; McHenry, Allison R.; Sun, Heather H.; Bray, Mark-Anthony; Viramontes, Omar; Machaidze, Revaz; Brastianos, Priscilla K.; Reardon, David A.; Dunn, Ian F.; Freeman, Gordon J.; Ligon, Keith L.; Carpenter, Anne E.; Alexander, Brian M.; Agar, Nathalie Y.; Rodig, Scott J.; Bradshaw, Elizabeth M.; Santagata, Sandro (Impact Journals LLC, 2015)
      There are no effective medical treatments for WHO grade III (anaplastic) meningioma. Patients with this high-grade malignancy have a median survival of less than two years. Therapeutics that modulate the mechanisms that ...
    • Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation 

      Van Allen, Eliezer Mendel; Golay, H. G.; Liu, Yan; Koyama, S.; Wong, Kwok-Kin; Taylor-Weiner, Amaro; Giannakis, Marios; Harden, M.; Rojas-Rudilla, V.; Chevalier, A.; Thai, T.; Lydon, C.; Mach, S.; Wong, J. A.; Rabin, A. R.; Helmkamp, J.; Sholl, Lynette Marie; Carter, Scott Lambert; Oxnard, Geoffrey Raymond; Janne, Pasi Antero; Getz, Gad A; Lindeman, Neal I.; Hammerman, Peter Seth; Garraway, Levi Alexander; Hodi, Frank Stephen; Rodig, Scott J.; Dranoff, G; Wong, Kwok-Kin; Barbie, David Allen (American Association for Cancer Research (AACR), 2015)
      PD-1 immune checkpoint blockade occasionally results in durable clinical responses in advanced metastatic cancers. However, mechanism-based predictors of response to this immunotherapy remain incompletely characterized. ...
    • Mutations in G protein β subunits promote transformation and kinase inhibitor resistance 

      Yoda, Akinori; Adelmant, Guillaume; Tamburini, Jerome; Chapuy, Bjoern; Shindoh, Nobuaki; Yoda, Yuka; Weigert, Oliver; Kopp, Nadja; Wu, Shuo-Chieh; Kim, Sunhee S; Liu, Huiyun; Tivey, Trevor; Christie, Amanda L; Elpek, Kutlu G; Card, Joseph; Gritsman, Kira; Gotlib, Jason; Deininger, Michael W; Makishima, Hideki; Turley, Shannon J.; Javidi-Sharifi, Nathalie; Maciejewski, Jaroslaw P; Jaiswal, Siddhartha; Ebert, Benjamin L.; Rodig, Scott J.; Tyner, Jeffrey W; Marto, Jarrod; Weinstock, David Marc; Lane, Andrew Alan (Nature Publishing Group, 2014)
      Activating mutations in genes encoding G protein α (Gα) subunits occur in 4-5% of all human cancers, but oncogenic alterations in Gβ subunits have not been defined. Here we demonstrate that recurrent mutations in the Gβ ...
    • Next-Generation cDNA Screening for Oncogene and Resistance Phenotypes 

      Shindoh, Nobuaki; Weigert, Oliver; Bird, Liat; Yoda, Akinori; Yoda, Yuka; Sullivan, Timothy J.; Lane, Andrew Alan; Kopp, Nadja; Rodig, Scott J.; Fox, Edward Alvin; Weinstock, David Marc (Public Library of Science, 2012)
      There is a pressing need for methods to define the functional relevance of genetic alterations identified by next-generation sequencing of cancer specimens. We developed new approaches to efficiently construct full-length ...
    • An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma 

      Drier, Yotam; Cotton, Matthew J.; Williamson, Kaylyn E.; Gillespie, Shawn M.; Ryan, Russell J.H.; Kluk, Michael J.; Carey, Christopher D.; Rodig, Scott J.; Sholl, Lynette M; Afrogheh, Amir H.; Faquin, William C.; Queimado, Lurdes; Qi, Jun; Wick, Michael J.; El-Naggar, Adel K.; Bradner, James E.; Moskaluk, Christopher A.; Aster, Jon C.; Knoechel, Birgit; Bernstein, Bradley E. (2016)
      Translocation events are frequent in cancer and may create chimeric fusions or ‘regulatory rearrangements’ that drive oncogene overexpression. Here we identify super-enhancer translocations that drive overexpression of the ...
    • Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer 

      Bowman-Colin, Christian; Xia, B.; Bunting, S.; Klijn, C.; Drost, R.; Bouwman, P.; Fineman, L.; Chen, X.; Culhane, Aedin; Cai, H.; Rodig, Scott J.; Bronson, Roderick Terry; Jonkers, J.; Nussenzweig, A.; Kanellopoulou, C.; Livingston, David Morse (Proceedings of the National Academy of Sciences, 2013)
      Germ-line mutations in PALB2 lead to a familial predisposition to breast and pancreatic cancer or to Fanconi Anemia subtype N. PALB2 performs its tumor suppressor role, at least in part, by supporting homologous ...
    • RelA-Induced Interferon Response Negatively Regulates Proliferation 

      Kochupurakkal, Bose S; Wang, Zhigang C.; Hua, Tony; Culhane, Aedin; Rodig, Scott J.; Rajkovic-Molek, Koraljka; Lazaro, Jean-Bernard; Richardson, Andrea; Biswas, Debajit Kumar; Iglehart, James Dirk (Public Library of Science (PLoS), 2015)
      Both oncogenic and tumor-suppressor activities are attributed to the Nuclear Factor kappa B (NF-kB) pathway. Moreover, NF-kB may positively or negatively regulate proliferation. The molecular determinants of these opposing ...
    • ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas 

      Sholl, Lynette Marie; Sun, Heather; Butaney, Mohit; Zhang, Chengsheng; Lee, Charles; Janne, Pasi Antero; Rodig, Scott J. (Ovid Technologies (Wolters Kluwer Health), 2013)
      ROS1 gene rearrangements are reported in 1–2% of lung adenocarcinomas (ACA) and are associated with response to the multitargeted tyrosine kinase inhibitor, crizotinib. ROS1 rearrangements can be detected using fluorescence ...
    • Targeting CD22 Reprograms B-Cells and Reverses Autoimmune Diabetes 

      Dada, Shirine; Wong, Masie; Law, Kenneth; Wu, Erxi; Dunussi-Joannopoulos, Kyri; Bluestone, Jeffrey; Fiorina, Paolo; Vergani, Andrea; Jurewicz, Mollie; Tian, Ze; Abdi, Reza; Guleria, Indira; Rodig, Scott J.; Sayegh, Mohamed Hassan (American Diabetes Association, 2008)
      OBJECTIVES—To investigate a B-cell–depleting strategy to reverse diabetes in naïve NOD mice. RESEARCH DESIGN AND METHODS—We targeted the CD22 receptor on B-cells of naïve NOD mice to deplete and reprogram B-cells to ...
    • Taxonomy of breast cancer based on normal cell phenotype predicts outcome 

      Santagata, Sandro; Thakkar, Ankita; Ergonul, Ayse; Wang, Bin; Woo, Terri; Hu, Rong; Harrell, J. Chuck; McNamara, George; Schwede, Matthew; Culhane, Aedin; Kindelberger, David; Rodig, Scott J.; Richardson, Andrea; Schnitt, Stuart Jay; Tamimi, Rulla May; Ince, Tan A. (American Society for Clinical Investigation, 2014)
      Accurate classification is essential for understanding the pathophysiology of a disease and can inform therapeutic choices. For hematopoietic malignancies, a classification scheme based on the phenotypic similarity between ...